Forbion-backed biotech Progentos debuts with $65M for MS drug [Yahoo! Finance]
Korro Bio, Inc. (KRRO)
Company Research
Source: Yahoo! Finance
The company, Progentos Therapeutics, has raised $65 million through a Series A financing that also involved Alta Partners, Mission BioCapital, Longwood Fund and Dolby Family Ventures. Progentos says the money will go toward expanding its pipeline and pushing a potential treatment for multiple sclerosis through "proof of concept” testing. Progentos acquired its multiple sclerosis drug from Frequency Therapeutics , a spinout from the Massachusetts Institute of Technology. Formed about 10 years ago, Frequency was built around discoveries from the labs of Bob Langer at MIT and Jeffrey Karp at Harvard University. The startup went public in 2019. But after its main asset — an experimental therapy for hearing loss — disappointed in clinical testing, Frequency laid off about half its staff and later entered a reverse merger with RNA editing company Korro Bio. Frequency's drug fits into Progentos' broader aim, which is to develop new kinds of small molecule medicines that replace the my
Show less
Read more
Impact Snapshot
Event Time:
KRRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRRO alerts
High impacting Korro Bio, Inc. news events
Weekly update
A roundup of the hottest topics
KRRO
News
- Korro to Participate in Upcoming June Investor and Scientific ConferencesGlobeNewswire
- Korro Bio, Inc. (NASDAQ: KRRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.MarketBeat
- Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International ConferenceGlobeNewswire
- Korro Bio, Inc. (NASDAQ: KRRO) had its price target lowered by analysts at HC Wainwright from $115.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
- Korro Bio, Inc. (NASDAQ: KRRO) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $120.00 price target on the stock.MarketBeat
KRRO
Earnings
- 5/14/24 - Miss
KRRO
Sec Filings
- 6/21/24 - Form 424B3
- 6/21/24 - Form 424B3
- 6/21/24 - Form 8-K
- KRRO's page on the SEC website